Core Viewpoint - The company has initiated Phase I clinical trials for its inhaled tuberculosis vaccine in Indonesia, marking a significant step in its vaccine development efforts [1] Group 1: Vaccine Development - The inhaled tuberculosis vaccine, developed using a 5-type adenovirus vector, aims to enhance immunity in individuals previously vaccinated with the BCG vaccine [1] - The BCG vaccine is currently the only vaccine available for tuberculosis prevention, but its efficacy diminishes over time, necessitating the development of a booster vaccine [1] - The company has successfully completed Phase Ia and Ib clinical trials in Canada, demonstrating the safety and efficacy of the tuberculosis booster vaccine [1] Group 2: Technological Advancements - The company has leveraged its experience from developing inhaled COVID-19 vaccines to establish a comprehensive inhalation pharmaceutical and quality control system [1] - The upgraded inhaled tuberculosis booster vaccine includes additional antigen components and is designed to be delivered via nebulization, potentially stimulating pulmonary immune responses [1] - This innovative delivery method aims to clear tuberculosis bacteria, control latent infections, and provide preventive effects against the disease [1]

康希诺生物股份公司（以下简称"公司"）开发的吸入用肺结核疫苗（5型 腺病毒载体）（以下简称"吸入用结核病加强疫苗"）近日于印度尼西亚启动I 期临床试验，并完成I期临床首例受试者入组。 一、产品基本情况 证券代码：688185 证券简称：康希诺 公告编号：2025-041 康希诺生物股份公司 自愿披露关于吸入用肺结核疫苗（5型腺病毒载体）于 印度尼西亚启动I期临床试验并完成首例受试者入组的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 11 月 14 日 目前，卡介苗是全球唯一可用于预防结核病的疫苗，在全球范围内被广泛接 种，其对预防婴幼儿结核病发挥重要作用，但卡介苗保护力会随时间减弱，无法 通过加强免疫接种增强疫苗的保护效果。针对此不足，公司研发了第一代全球创 新的结核病加强疫苗用于卡介苗接种人群，该款疫苗于加拿大完成了 Ia 及 Ib 期 临床试验，临床数据证明了该候选疫苗的安全性和作为卡介苗加强疫苗的有效 性，以及黏膜免疫的优越性。 基于吸入用新冠疫苗开发的技术累积，公司建立了完整的吸入药学、质量控 ...

康希诺11月13日公告，公司开发的吸入用肺结核疫苗（5型腺病毒载体）近日于印度尼西亚启动I期临床 试验，并完成首例受试者入组。该疫苗为第一代全球创新的结核病加强疫苗，通过雾化吸入的方式递 送，有望激发肺部免疫应答，控制潜伏感染，并可实现预防感染的效果。 ...

Core Viewpoint - The company, CanSino (688185.SH), has initiated Phase I clinical trials for its inhaled tuberculosis vaccine in Indonesia, marking a significant step in its development process [1] Group 1: Clinical Trial Details - The Phase I clinical trial aims to explore the safety and immunogenicity of a single dose of the inhaled tuberculosis vaccine (Ad5 vector) in adults aged 18-49 [1] - The first subject has been enrolled in the Phase I clinical trial, indicating progress in the vaccine's development timeline [1]

Core Viewpoint - The company, CanSino (688185.SH), has initiated Phase I clinical trials for its inhaled tuberculosis vaccine in Indonesia, marking a significant step in its vaccine development efforts [1] Group 1: Clinical Trial Details - The Phase I clinical trial aims to explore the safety and immunogenicity of a single dose of the inhaled tuberculosis vaccine (Ad5 vector) in adults aged 18-49 [1]

Group 1 - The 11th batch of national organized drug procurement results has been officially announced, set to be implemented in February 2026 [1] - A total of 55 drugs have been included in this procurement, covering commonly used medications in areas such as anti-infection, anti-allergy, anti-tumor, blood sugar reduction, blood pressure reduction, blood lipid reduction, and anti-inflammatory pain relief [1] - The average price difference for selected drugs in this procurement has narrowed to 1.7 times, with 8 varieties initiating a price correction mechanism to maintain normal pricing order [1] Group 2 - During the 14th Five-Year Plan period, China has approved 210 innovative drugs and 269 innovative medical devices, both showing accelerated growth [1] - China's biopharmaceutical market has become the second largest globally, with approximately 30% of global innovative drugs under research [1] - In the first half of 2025, the total amount of innovative drug licensing agreements reached nearly $66 billion, indicating increasing global recognition of Chinese innovative drugs [1] Group 3 - As of November 12, 2025, the three major A-share indices collectively adjusted, with the Shanghai Composite Index down 0.14%, Shenzhen Component Index down 0.62%, and ChiNext Index down 0.81% [2] - The Kexin Pharmaceutical ETF (588130) rose by 1.22%, with the latest quote at 1.164 yuan and a turnover rate of 7.36% [2] - Among component stocks, Hejing Biological led with an increase of 8.23%, while several other stocks showed mixed performance [2]

2025 年第二次临时股东大会会议资料 2025 年 11 月 康希诺生物股份公司 2025 年第二次临时股东大会 证券代码：688185 证券简称：康希诺 康希诺生物股份公司 | 年第二次临时股东大会会议议案 6 2025 | | --- | | 议案一：关于取消监事会、修订《公司章程》及其附件并办理工商变更登记的议案 6 | | 议案二：关于修订部分公司治理制度的议案 7 | | 议案三：关于使用公积金弥补亏损的议案 8 | | 议案四：关于选举第三届董事会独立非执行董事的议案 10 | 康希诺生物股份公司 2025 年第二次临时股东大会 康希诺生物股份公司 2025 年第二次临时股东大会会议须知 为维护全体股东的合法权益，确保股东大会会议秩序和议事效率，保证股东 大会的顺利召开，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、中国证监会《上市公 司股东会规则》以及《康希诺生物股份公司章程》（以下简称"《公司章程》"） 和《康希诺生物股份公司股东大会议事规则》等有关规定，特制定康希诺生物股 份公司（以下简称"公司"）2025 年第二次临时股东大 ...

Macro Strategy - In October, China's exports showed a year-on-year decline of -1.10%, marking the first negative growth since March 2025, which affected the cumulative year-on-year growth rate, decreasing from 6.10% in September to 5.30% in October. This decline is attributed to a high base in October 2024 and a temporary escalation in trade conflicts between China and the US in early October 2025 [3][4]. Market Overview - From November 3 to November 7, 2025, A-share indices experienced wide fluctuations, with the Shanghai Composite Index rising by 1.08% and the ChiNext Index increasing by 0.65%. The market is expected to continue a "slow bull" trend with wide fluctuations in November due to reduced short-term trade conflict risks between China and the US [4][5]. - Among the 31 first-level industries, the top performers were electric equipment and coal, with weekly increases of 4.98% and 4.52%, respectively. Conversely, the beauty care and computer sectors saw declines of -3.10% and -2.54% [6][7]. North Exchange Market - As of November 7, 2025, the North Exchange had 282 listed stocks, with an average total market value of 908.24 billion yuan, reflecting a 1.24% increase from the previous week. The liquidity decreased, with average trading volume dropping by 17.23% [11][12]. - The highest weekly gain was recorded by Danna Biological, which surged by 377.78% in its first week of trading, while the largest decline was seen in Beiyikang, which fell by 12.35% [13]. Vaccine Industry - The vaccine industry is experiencing structural differentiation, with companies like Kangtai Biological and Zhonghui Biological making significant advancements in vaccine development for specific populations, such as infants and pregnant women. The updated technical guidelines emphasize the importance of vaccination for high-risk groups [17][21]. - The vaccine sector's performance remains under pressure, with a year-to-date decline of -1.57%. The industry is focusing on innovation and international expansion to navigate current challenges [19][21]. - The vaccine sector's price-to-earnings ratio (PE) is currently at 99.07X, reflecting a decrease of 4.97X from the previous week, while the price-to-book ratio (PB) remains stable at 1.94X [20]. Investment Recommendations - The vaccine industry is advised to focus on innovation and international markets, as the current market conditions present challenges due to supply-demand imbalances and intense competition. Companies with strong technological capabilities and differentiated product lines are recommended for investment [21][23].

Group 1 - The company will hold its second extraordinary general meeting of shareholders on November 27, 2025 [2] - A temporary proposal has been added to the agenda, suggesting the use of capital reserves to cover losses [3][19] - The proposal was submitted by Dr. Xuefeng Yu, who holds 7.26% of the company's shares [2][3] Group 2 - The meeting will take place at the Tianjin East Hyatt Hotel, starting at 14:00 [5] - Shareholders can vote online through the Shanghai Stock Exchange's voting system on the day of the meeting [7] - The original date for the equity registration remains unchanged [8] Group 3 - The company reported a cumulative undistributed profit of -1,450,342,128.90 yuan as of December 31, 2024 [17] - The plan involves using 118,388,703.29 yuan from surplus reserves and 1,331,953,425.61 yuan from capital reserves to offset losses [18] - After the implementation of this plan, the company's surplus reserves will be reduced to 0 yuan, and capital reserves will decrease to 5,244,776,299.42 yuan [19] Group 4 - The proposal to use capital reserves to cover losses has been approved by the company's board and supervisory board [20] - The company aims to enhance investor returns and promote high-quality development through this measure [19] - The proposal requires approval from the shareholders' meeting, indicating a level of uncertainty [21] Group 5 - The company will hold a quarterly performance briefing on November 17, 2025, to discuss the third quarter results [23][25] - Investors can submit questions in advance through the Shanghai Stock Exchange's website or via email [24][27] - The meeting will be conducted in an interactive online format [29]

关于 2025 年第二次临时股东大会增加临时提案 的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、股东大会有关情况 证券代码：688185 证券简称：康希诺 公告编号：2025-039 康希诺生物股份公司 1. 股东大会的类型和届次： 2025 年第二次临时股东大会 | 股份类别 | 股票代码 | 股票简称 | 股权登记日 | | --- | --- | --- | --- | | A 股 | 688185 | 康希诺 | 2025/11/21 | 二、增加临时提案的情况说明 公司已于 2025 年 10 月 28 日公告了股东大会召开通知，单独持有 7.26%股 份的股东 XUEFENG YU（宇学峰）博士，在 2025 年 11 月 6 日提出临时提案并 书面提交股东大会召集人。股东大会召集人按照《上海证券交易所科创板上市公 司自律监管指引第 1 号—规范运作》有关规定，现予以公告。 3. 临时提案的具体内容 2. 股东大会召开日期：2025 年 11 月 27 日 3. 股东大会股权登记日： 1. 提案人： ...